- Home
- CISS vs NCNA Comparison
CISS vs NCNA Comparison
Compare CISS & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- NCNA
- Stock Information
- Founded
- CISS 2022
- NCNA 1997
- Country
- CISS Greece
- NCNA United Kingdom
- Employees
- CISS N/A
- NCNA N/A
- Industry
- CISS Marine Transportation
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- NCNA Health Care
- Exchange
- CISS Nasdaq
- NCNA Nasdaq
- Market Cap
- CISS 5.3M
- NCNA 4.3M
- IPO Year
- CISS N/A
- NCNA 2017
- Fundamental
- Price
- CISS $1.23
- NCNA $1.14
- Analyst Decision
- CISS
- NCNA Buy
- Analyst Count
- CISS 0
- NCNA 2
- Target Price
- CISS N/A
- NCNA $25.00
- AVG Volume (30 Days)
- CISS 168.3K
- NCNA 238.3K
- Earning Date
- CISS 11-18-2024
- NCNA 11-25-2024
- Dividend Yield
- CISS N/A
- NCNA N/A
- EPS Growth
- CISS N/A
- NCNA N/A
- EPS
- CISS N/A
- NCNA N/A
- Revenue
- CISS $46,661,732.00
- NCNA N/A
- Revenue This Year
- CISS N/A
- NCNA N/A
- Revenue Next Year
- CISS N/A
- NCNA N/A
- P/E Ratio
- CISS N/A
- NCNA N/A
- Revenue Growth
- CISS 491.48
- NCNA N/A
- 52 Week Low
- CISS $1.17
- NCNA $0.96
- 52 Week High
- CISS $49.25
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- CISS 33.66
- NCNA 43.15
- Support Level
- CISS $1.24
- NCNA $0.96
- Resistance Level
- CISS $1.36
- NCNA $1.37
- Average True Range (ATR)
- CISS 0.14
- NCNA 0.15
- MACD
- CISS 0.01
- NCNA -0.00
- Stochastic Oscillator
- CISS 8.00
- NCNA 26.09
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.